Publications by authors named "Timothy Mant"

Claim this Profile
P
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.
Michael A Tortorici, Danielle Duffy, Rebecca Evans, John Feaster, Andreas Gille, Timothy G K Mant

Clin Pharmacol Drug Dev· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Athiwat Hutchaleelaha, Mira Patel, Carla Washington, Vincent Siu, Elizabeth Allen, Timothy Mant

Br J Clin Pharmacol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Jo Howard, Claire Jane Hemmaway, Paul Telfer, D Mark Layton, John Porter, Timothy Mant

Blood· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects.
Mitul A Mehta, Anne Schmechtig, Vasileia Kotoula, Juliet McColm, Kimberley Jackson, Timothy Mant

Psychopharmacology (Berl)· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease.
Paul Telfer, Irene Agodoa, Kathleen M Fox, Laurie Burke, Timothy Mant

Hematol Rep· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.
Ken Grime, Rikard Pehrson, Pär Nordell, Michael Gillen, Wolfgang Kühn, Timothy Mant

Br J Clin Pharmacol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis.
Bruce Kirkham, Khaldoun Chaabo, Christopher Hall, Toby Garrood, Timothy Mant

Rheumatology (Oxford)· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Joseph A Jakubowski, Chunmei Zhou, Kenneth J Winters, D Richard Lachno, Jo Howard, Timothy Mant

Platelets· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation.
Joseph A Jakubowski, Chunmei Zhou, Stipo Jurcevic, Kenneth J Winters, D Richard Lachno, Timothy G Mant

Thromb Res· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga-Morskaya, Abigail Liebow, Brian R Bettencourt, Timothy Mant

Lancet· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
Teresa Coelho, David Adams, Ana Silva, Pierre Lozeron, Philip N Hawkins, Timothy Mant

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.
Joseph A Jakubowski, Chunmei Zhou, David S Small, Kenneth J Winters, D Richard Lachno, Timothy G Mant

Br J Clin Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a cytokine inhibitor, JTE-607, on the response to endotoxin in healthy human volunteers.
Svetlana Borozdenkova, Timothy G K Mant, Elizabeth Allen, Kewei Pu, Shoji Hoshino

Int Immunopharmacol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in HLA-DR expression, cytokine production and coagulation following endotoxin infusion in healthy human volunteers.
Timothy G K Mant, Svetlana Borozdenkova, Daniel B A Bradford, Elizabeth Allen, Dipti M Amin

Int Immunopharmacol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.
Kimberly E Vanover, Doris Robbins-Weilert, Darren G Wilbraham, Timothy G K Mant, Daniel P van Kammen

J Clin Pharmacol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.
Kimberly E Vanover, Doris Robbins-Weilert, Darren G Wilbraham, Timothy G K Mant, Daniel P van Kammen

J Clin Pharmacol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers.
Timothy G K Mant, Daniel Bradford, Dipti M Amin, Jaya Pisupati, Yoshikazu Kambayashi

Br J Clin Pharmacol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
K Lea Sewell, Richard S Geary, Brenda F Baker, Josephine M Glover, Timothy G K Mant

J Pharmacol Exp Ther· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers.
Timothy Mant, Philippe Fournié, Céline Ollier, François Donat, José Necciari

Clin Pharmacokinet· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis